Clinical trial
Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in…
NCT00353756 · Avidia, Industry · Unknown status
Key facts
| NCT number | NCT00353756 |
|---|---|
| Title | Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease |
| Official title | A Placebo-Controlled, Phase 1, Single and Multiple IV Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn's Disease |
| Lead sponsor | Avidia, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | C326, IL-6 Inhibitory Avimer protein |
| Enrollment | 52 |
| Start date | Sep 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Jul 19, 2006 |
| Last update posted | Oct 11, 2006 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: